. Author manuscript; available in PMC: 2012 Feb 15.

Published in final edited form as: Clin Cancer Res. 2010 Sep 15;17(4):918–927. doi: 10.1158/1078-0432.CCR-10-0515

Table 5.

Univariate analysis of correlation between non-hematologic toxicities and outcome after sunitinib treatment: overall survival (OS) and time-to-progression (TTP). Data are shown as hazard ratios with 95% CI. P values are from Wald test, after adjusting for baseline labs and BCLC stage (n=34)

Adverse effect	OS		TTP

	All grades	Grades ³2	All grades	Grades ³2
Fatigue	0.45 [0.19,1.11]	1.47 [0.53,4.10]	*0.32 [0.12,0.82]*	0.91 [0.32,2.55]
P value	0.084	0.46	0.017	0.85

Skin toxicities¹	*0.24 [0.09,0.68]*	0.27 [0.06,1.19]	*0.31 [0.12,0.81]*	0.38 [0.12,1.19]
P value	0.0075	0.083	0.017	0.097

Nausea or vomiting	1.32 [0.55,3.19]	*6.03 [1.94,18.75]*	0.84 [0.35,1.98]	1.38 [0.31,6.09]
P value	0.53	0.0019	0.69	0.67

Note that HR < 1 indicates decreased hazard of death or disease progression associated with toxicities, after adjusting for BCLC class.

Skin toxicities included: Hand-foot reaction, rash/desquamation, rash: acne/acneiform, dry skin.